EU MDR costing smaller medtechs 5% of their annual sales: survey




  • Almost half of medtech companies expect to spend 5% or more of their annual revenue on the EU Medical Device Regulation, results of a 101-company survey conducted by German software company Climedo Health suggest.


  • The firm's analysis of survey data reported that hiring extra staff, investing in clinical development and the initiation of other activities needed to comply with the delayed-but-still-looming European Union regulation are driving up costs at medtech companies.


  • The costs are, in part, a reflection of ongoing uncertainty about the impact of MDR. Almost 70% of the surveyed companies spend most of their MDR-focused time trying to understand the new requirements.



Read More


7 views

Contact Us

Tel: +44 (0) 1603 626 960

Email: info@uropharma.com

Social Media

  • LinkedIn Social Icon

Linkedin.com/company/uropharma

  • Twitter

Twitter.com/UroPharma

  • Facebook

Facebook.com/bladdercontrol

©2017-2020 UroPharma, Inc. All Rights Reserved